Get started
Author

Diego Silveira da Silva

Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis
2017 · Michael G. Dwyer, Diego Silva, et al. · NeuroImage Clinical · 59
PDF
Assessing ‘No Evidence of Disease Activity’ Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study
2017 · On behalf of the MS-MRIUS Study Group, Bianca Weinstock-Guttman, et al. · CNS Drugs · 36
PDF
Effects of aerobic, resistance and combined training on endothelial function and arterial stiffness in older adults: A systematic review and meta-analysis
2024 · Raphael Silveira Nunes da Silva, Diego Silveira da Silva, et al. · PLoS ONE · 35
Establishing pathological cut-offs for lateral ventricular volume expansion rates
2018 · Michael G. Dwyer, Jesper Hagemeier, et al. · NeuroImage Clinical · 29
PDF
Effects of Cocoa Consumption on Cardiometabolic Risk Markers: Meta-Analysis of Randomized Controlled Trials
2024 · Tainah O. P. Arisi, Diego Silveira da Silva, et al. · Nutrients · 20
Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis
2021 · Bruce AC Cree, Jeffrey A Cohen, et al. · Multiple Sclerosis Journal · 17
White matter lesion location correlates with disability in relapsing multiple sclerosis
2020 · Laura Gaetano, Baldur Magnusson, et al. · Multiple Sclerosis Journal - Experimental Translational and Clinical · 17
Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS‐MRIUS
2018 · Robert Zivadinov, Jennie Medin, et al. · Journal of Neuroimaging · 13
Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION―A 2-Year, Multicenter, Observational, Cohort Study
2022 · Helmut Butzkueven, Paul S. Giacomini, et al. · Brain Sciences · 11
PDF
Salient Central Lesion Volume: A Standardized Novel Fully Automated Proxy for Brain FLAIR Lesion Volume in Multiple Sclerosis
2019 · Michael G. Dwyer, Niels Bergsland, et al. · Journal of Neuroimaging · 10
Comparison of first-line and second-line use of fingolimod in relapsing MS: The open-label EARLIMS study
2020 · Oscar Fernández, Guillermo Izquierdo, et al. · Multiple Sclerosis Journal - Experimental Translational and Clinical · 9
Early initiation of fingolimod reduces the rate of severe relapses over the long term: Post hoc analysis from the FREEDOMS, FREEDOMS II, and TRANSFORMS studies
2019 · Judith Haas, Douglas Jeffery, et al. · Multiple Sclerosis and Related Disorders · 9
No evidence of disease activity in patients receiving fingolimod at private or academic centers in clinical practice: a retrospective analysis of the multiple sclerosis, clinical, and magnetic resonance imaging outcomes in the USA (MS-MRIUS) study
2018 · Robert Zivadinov, Nasreen Khan, et al. · Current Medical Research and Opinion · 7
Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study
2018 · Robert Zivadinov, Jennie Medin, et al. · Multiple Sclerosis and Related Disorders · 6
Evaluating No Evidence of Disease Activity in Patients With Relapsing Multiple Sclerosis: Post Hoc Analysis of the Phase 3 RADIANCE and Open-Label Extension Studies of Ozanimod (P7-4.012)
2022 · Ludwig Kappos, Giancarlo Comi, et al. · Neurology · 4
Effects of cocoa consumption on cardiometabolic risk markers: Protocol for a systematic review and meta-analysis of randomized controlled trials
2024 · Tainah Ortiz Pinto Arisi, Diego Silveira da Silva, et al. · PLoS ONE · 3
PDF
Neurological Software Tool for REliable Atrophy Measurement (NeuroSTREAM) in Multiple Sclerosis (S45.005)
2016 · Michael Dwyer, Diego Silva, et al. · Neurology · 3
Early Fingolimod Treatment Improves Disease Outcomes at 2 and 4 years in Patients with Relapsing-Remitting Multiple Sclerosis (P6.332)
2017 · Reinhard Hohlfeld, Ludwig Kappos, et al. · Neurology · 2
RNFL as a Surrogate Outcome Marker in Patients with Multiple Sclerosis: Design of the OCTiMS study, Baseline Characteristics and OCT Test Reproducibility (P7.224)
2015 · Peter Calabresi, Frederik Barkhof, et al. · Neurology · 2
A Hybrid Framework for Quantifying and Analyzing the Structural Properties of Human Retinal Vessel Networks
2025 · Hitalo Silva, Diego Silva, et al. · Springer proceedings in complexity · 1
A Hybrid Approach to Quantify the Structure and Dynamics of Vascular System
2025 · Hitalo Silva, Carmelo Bastos-Filho, et al. · Lecture notes in networks and systems · 1
Artificial Intelligence-based Thalamic Volumetry Is Fast, Reliable, and Generalizable to Large, Heterogeneous Datasets Using Only Clinical Quality T2-FLAIR MRI (4846)
2020 · Michael Dwyer, Daniel Brior, et al. · Neurology · 1
Whole Brain and Lateral Ventricular Volume Changes are associated with Development of Disability Progression in Multiple Sclerosis: Results from a Large-Scale Clinical Routine 5-Year Observational Study (P3.356)
2018 · Emanuele Ghione, Michael Dwyer, et al. · Neurology · 1
Long-Term Efficacy of Early Fingolimod Treatment in Young Adult Patients With Relapsing Multiple Sclerosis (P6.385)
2018 · Tanuja Chitnis, Diego Silva, et al. · Neurology · 1
Assessing no evidence of disease activity status in patients with relapsing–remitting multiple sclerosis receiving fingolimod: results from a longitudinal, multicenter, real-world study (P4.388)
2017 · Bianca Weinstock-Guttman, Jennie Medin, et al. · Neurology · 1
Works count: 41
Citation count: 300
H-index: 10
I10-index: 10
Year
Topic
Type